e15547 Background: Ovarian cancer is the one of three malignant tumor in the department of gynecology. As the development of population aging, there is a trend of increasing ovarian cancer incidence rate.The traditional therapeutic tool of ovarian cancer lack tumor tissue specificity, so targeted therapy become a new tendency of the ovarian cancer therapy. Chemoresistance remains a major therapeutic problem. Researching new chemotherapeutics and overcoming drug resistance is a key to successful treatment of ovarian cancer. Methods: In this experiment the SKOV-3,SKOV-3/DDP cell growth inhibiting rates, the cellular apoptosis percentage, cell cycle phase and the expression of apoptosis relative protein were examined by MTT assay, Annextin V/PI assay, immunohistochemistry assay methods. Results: We found that Bortezomib can actively inhibit the growth of SKOV-3,SKOV-3/DDP cell line, induce them apoptosis, and together with DDP can effectively enhance the inhibiting effect to SKOV-3/DDP cell line. The mechanism of Bortezomib suppressing SKOV-3/DDP cell line growth is that the G2/M phase cell growth was blocked, and when Bortezomib was used with DDP together, the S phase cell growth was blocked. In addition, the mechanism of Bortezomib inducing SKOV-3,KOV-3/DDP cell line apoptosis maybe related with antiapoptotic proteins Bcl-2 expression level decrease, and proapoptotic proteins Bad expression level increase. Conclusions: Although we only did the relative research of Bortezomib treatment to ovarian cancer in vitro, confirmed that its effectiveness on ovarian cancer. This may provide the new treatment ideas and experiment support for ovarian cancer chemotherapy and recrudescent and refractory ovarian cancer treatment, and also may provide clinical guide for solid tumors treatment and multidrug resistance reversion.